Advertisement

Hyperthermic Intraperitoneal Chemotherapy in Nongynecologic Cancers

  • Bing Yi
  • Jason M. Foster
  • Brian W. Loggie
Part of the Current Clinical Oncology book series (CCO)

Abstract

Cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) has had a significant impact in the management of peritoneal surface malignancies of nongynecologic origin. It has improved the quality and quantity of life for these patients. Evidence of improved median survival has been observed independent of the origin of the carcinomatosis, and this treatment paradigm resulted in measurable 5-yr survival in diseases where it did not exist before the use of CRS + HIPEC.

Key Words

Peritoneal carcinomatosis MPM malignant peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy CRS gastrointestinal 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol 2001;8:632–637.PubMedCrossRefGoogle Scholar
  2. 2.
    Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989;63:364–367.PubMedCrossRefGoogle Scholar
  3. 3.
    Yazdi GP, Miedema BW, Humphrey LJ. High mortality after abdominal operation in patients with large volume MA. J Surg Oncol 1996;62:93–96.PubMedCrossRefGoogle Scholar
  4. 4.
    Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358–363.PubMedCrossRefGoogle Scholar
  5. 5.
    Fleming RA, Loggie BW, Russell GB, et al. Systemic exposure of mitomycin C during intraperitoneal administration is correlated with hematologic toxicity and survival in patients with peritoneal carcinomatosis (Abstract). Proc Am Assoc Cancer Res 1998;39:599.Google Scholar
  6. 6.
    Harmon BV, Corder AM, Collings RJ, et al. Cell death induced in a murine mastocytoma by 42–47 degrees C heating in vitro: Evidence that the form of death changes from apoptosis to necrosis above a critical head load. Int J Radiat Biol 1990;58:845–858.PubMedCrossRefGoogle Scholar
  7. 7.
    Wallner KE, Banda M, Li GC. Hyperthermic enhancement of cell killing by mitomycin C in mitomycin C-resistant Chinese hamster ovary cells. Cancer Res 1987;47:1308–1312.PubMedGoogle Scholar
  8. 8.
    Yao K, Clayton M, O’Dwyer PJ. Interaction of heat and hypoxia in modulating transcription of DT-diaphorase in human colon adenocarcinoma cells. Cell Growth Differ 1994;5:125–131.PubMedGoogle Scholar
  9. 9.
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Loggie BW, Fleming RA, McQuellon RP, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000;66:561–568.PubMedGoogle Scholar
  11. 11.
    Loggie BW, Fleming RA. Complications of heated intraperitoneal chemotherapy and strategies for prevention. In: Sugarbaker PH, ed. Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer Academic Publishers; 1996:221–233.Google Scholar
  12. 12.
    McGory ML, Maggard MA, Kang H, et al. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum 2005;48:2264–2271.PubMedCrossRefGoogle Scholar
  13. 13.
    Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathological analysis of appendiceal tumors from 7970 appendectomies. Dis Colon Rectum 1998;41:75–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Nitecki SS, Wolff BG, Schlinkart R, et al. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 1994;219:51–57.PubMedCrossRefGoogle Scholar
  15. 15.
    Gough DB, Donohue JH, Schutt JH, et al. Pseudomyxoma peritonei: Long-term patient survival with an aggressive regional approach. Ann Surg 1994;219:112–119.PubMedCrossRefGoogle Scholar
  16. 16.
    Sugarbaker PH. Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer. Cancer Invest 2005;23:155–172.PubMedCrossRefGoogle Scholar
  17. 17.
    Sugarbaker PH, Zhu BW, Sese GB, et al. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993;36:323–329.PubMedCrossRefGoogle Scholar
  18. 18.
    Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001;27:239–243.PubMedCrossRefGoogle Scholar
  19. 19.
    Stewart JH, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006;13:1–11.CrossRefGoogle Scholar
  20. 20.
    Elias D, Sideris L, Liberale G, et al. Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery 2005;137:411–416.PubMedCrossRefGoogle Scholar
  21. 21.
    Aizawa M, Watanabe O, Naritaka Y, et al. Adenocarcinoid of the appendix: report of two cases. Surg Today 2003;33:375–378.PubMedCrossRefGoogle Scholar
  22. 22.
    Butler JA, Houshiar A, Lin F, et al. Goblet cell carcinoid of the appendix. Am J Surg 1994;168:685–687.PubMedCrossRefGoogle Scholar
  23. 23.
    Mahteme H, Sugarbaker PH. Treatment of peritoneal carcinomatosis from adenocarcinoid of appendiceal origin. Br J Surg 2004;91:1168–1173.PubMedCrossRefGoogle Scholar
  24. 24.
    Moran BJ, Mukherjee A, Sexton R. Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 2006;93:100–104.PubMedCrossRefGoogle Scholar
  25. 25.
    Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): A strategy that has confirmed its efficiency in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004;11:393–398.PubMedCrossRefGoogle Scholar
  26. 26.
    Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545–1550.PubMedCrossRefGoogle Scholar
  27. 27.
    Piso P, Bektas H, Werner U, et al. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol 2001;27:286–290.PubMedCrossRefGoogle Scholar
  28. 28.
    Culliford AT, Brooks AD, Sharma S, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001;8(10):754–755.CrossRefGoogle Scholar
  29. 29.
    Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69–76.PubMedCrossRefGoogle Scholar
  30. 30.
    Carraro PG, Segala M, Cesana BM, et al. Obstructing colonic cancer: failure and survival patterns over a ten-year follow-up after one-stage curative surgery. Dis Colon Rectum 2001;44:243–250.PubMedCrossRefGoogle Scholar
  31. 31.
    Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: A phase II study. J Clin Oncol 2003;21:799–806.PubMedCrossRefGoogle Scholar
  32. 32.
    Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multiple-institutional study. J Clin Oncol 2004;22:3284–3292.PubMedCrossRefGoogle Scholar
  33. 33.
    Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2003;11:178–186.CrossRefGoogle Scholar
  34. 34.
    Witkamp AJ, De Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intraoperative hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001;37:979–984.PubMedCrossRefGoogle Scholar
  35. 35.
    Verwaal VJ, Van Ruth S, de Bree E, et al. Randomized trial of cytoreductive and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–3743.PubMedCrossRefGoogle Scholar
  36. 36.
    Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol 2007;14(1):128–133.PubMedCrossRefGoogle Scholar
  37. 37.
    Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437–444.PubMedCrossRefGoogle Scholar
  38. 38.
    Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999;85:529–534.PubMedCrossRefGoogle Scholar
  39. 39.
    Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: Results of a prospective randomized trial. World J Surg 2001;25:985–990.PubMedCrossRefGoogle Scholar
  40. 40.
    Yonemura Y, Kawamura T, Nojima N, et al. Postoperative results of left upper abdominal evisceration for advanced gastric cancer. Hepatogastroenterology 2000;47:571–574.PubMedGoogle Scholar
  41. 41.
    MacDonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730.PubMedCrossRefGoogle Scholar
  42. 42.
    Pilati P, Rossi CR, Mocellin S, et al. Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol 2001;27:125–134.PubMedCrossRefGoogle Scholar
  43. 43.
    Hall J, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454–463.PubMedCrossRefGoogle Scholar
  44. 44.
    Antman K, Shemin R, Ryan L, et al. Benign and malignant mesothelioma. In: De Vita V, Hellman S, Rosenberg SA, eds. Principles and Practices of Oncology. Philadelphia: Lippincott, Williams, & Wilkins; 1993:1399–417.Google Scholar
  45. 45.
    Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67:999–1003.PubMedGoogle Scholar
  46. 46.
    Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560–4567.PubMedCrossRefGoogle Scholar
  47. 47.
    Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003;83:147–153.PubMedCrossRefGoogle Scholar
  48. 48.
    Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006;13:229–237.PubMedCrossRefGoogle Scholar
  49. 49.
    Sugarbaker PH, Acherman YIZ, Gonzalez-Moreno S, et al. Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience. Semin Oncol 2002;29:51–61.PubMedCrossRefGoogle Scholar
  50. 50.
    Aung TT, Davis MA, Ensminger WD, et al. Interaction between gemcitabine and mitomycin C in vitro. Cancer Chemther Pharmacol 2000;45:38–42.CrossRefGoogle Scholar
  51. 51.
    Van Bree C, Beumer C, Rodermond HM, et al. Effectiveness of 2′,2′difluorodeoxycytidine (gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hypertherm 1999;15:549–556.CrossRefGoogle Scholar
  52. 52.
    Schmidt U, Dahlke MH, Klempnauer J, et al. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005;31:53–58.PubMedCrossRefGoogle Scholar
  53. 53.
    Pilati P, Mocellin S, Rossi CR, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 2003;10:508–15.PubMedCrossRefGoogle Scholar
  54. 54.
    Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resesection and intraperitoneal chemotherapy. Cancer 2001;92:71–76.PubMedCrossRefGoogle Scholar
  55. 55.
    Stephens AD, Aldermann R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative chemotherapy using the Coliseum technique. Ann Surg Oncol 2000;6:790–796.CrossRefGoogle Scholar
  56. 56.
    Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003;138:26–33.PubMedCrossRefGoogle Scholar
  57. 57.
    Verwaal VJ, Van Tinteren H, Van Ruth S, et al. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cyotreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739–746.PubMedCrossRefGoogle Scholar
  58. 58.
    McQuellon RP, Loggie BW, Fleming RA, et al. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001;27:65–73.PubMedCrossRefGoogle Scholar
  59. 59.
    McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003;10:155–162.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Authors and Affiliations

  • Bing Yi
    • 1
  • Jason M. Foster
    • 1
  • Brian W. Loggie
    • 2
  1. 1.Department of Surgery, Creighton University Medical CenterCreighton UniversityOmaha
  2. 2.Creighton University Medical CenterCreighton UniversityOmaha

Personalised recommendations